Search Result

Results for "

nAChRs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	nAChR (198) 5-HT Receptor (6) Amyloid-β (2) Antibiotic (6) Apoptosis (3) Autophagy (4) Bacterial (3) Calcium Channel (4) Calmodulin (1) Cholinesterase (ChE) (4) Dengue virus (2) Endogenous Metabolite (3) ERK (2) Flavivirus (2) GABA Receptor (2) Histamine Receptor (2) HIV (2) HSV (2) Isotope-Labeled Compounds (6) JAK (1) mAChR (4) Microtubule/Tubulin (2) Mitophagy (2) NF-κB (2) NO Synthase (1) p38 MAPK (2) Parasite (11) Potassium Channel (2) SARS-CoV (3) STAT (1)
By Research Areas:	Cancer (17) Cardiovascular Disease (5) Infection (18) Inflammation/Immunology (19) Metabolic Disease (4) Neurological Disease (174)
Click Chemistry:	Alkynes (1)

207

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: nAChR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3654

α-Conotoxin S IA	nAChR	Neurological Disease
α-Conotoxin SIA is a selective nicotinic acetylcholine receptor (nAChR) antagonist with high affinity for the muscle nAChR. α-Conotoxin SIA preferentially targets the α/δ interface of the muscle nAChR in mouse muscle. In contrast, for Torpedo nAChR, α-Conotoxin SIA has a much higher affinity for the α/γ than for the α/δ interface .

HY-145299

nAChR modulator-1

nAChR Infection

nAChR modulator-1, a insecticide, is a insect nAChR orthosteric modulator .
HY-145300

nAChR modulator-2

nAChR Infection

nAChR modulator-2, a insecticide, is a insect nAChR orthosteric modulator .

nAChR modulator-1	nAChR	Infection
nAChR modulator-1, a insecticide, is a insect *nAChR* orthosteric modulator .

nAChR modulator-2	nAChR	Infection
nAChR modulator-2, a insecticide, is a insect *nAChR* orthosteric modulator .

HY-107686

5-Iodo-A-85380 dihydrochloride 5-I A-85380 dihydrochloride	nAChR	Neurological Disease
5-Iodo-A-85380 dihydrochloride is a selective ligand of *nAChR. 5-Iodo-A-85380 dihydrochloride binds to α4β2 nAChRs* in rat and human brain with K_ds of 12 and 14 pM,respectively .

HY-P5188A

Waglerin-1

nAChR GABA Receptor Neurological Disease

Waglerin-1, a 22-amino acid peptide, is a competitive antagonist of the muscle nicotinic receptor (nAChR) .

Waglerin-1	nAChR GABA Receptor	Neurological Disease
Waglerin-1, a 22-amino acid peptide, is a competitive antagonist of the muscle nicotinic receptor (nAChR) .

HY-10063

Ispronicline TC-1734; ACD3480	nAChR	Neurological Disease
Ispronicline (TC-1734), an orally active, brain-selective α4β2 nicotine acetylcholine receptor (nAChR) partial agonist, has shown memory-enhancing properties in rodents and a good tolerability profile. Ispronicline binds to the α4β2 nAChR with high affinity (K_i=11 nM) and is highly selective to other nAChRs such as α7 nAChR and α3β4 nAChR .

HY-136258

nAChR agonist CMPI hydrochloride	nAChR	Neurological Disease
nAChR agonist CMPI hydrochloride is a potent and selective positive allosteric modulator (PAM) of *nAChR* containing a α4:α4 subunit interface. nAChR agonist CMPI hydrochloride enhances the response of (α4)₃(β2)₂ nAChR to ACh (10 µM) with an EC₅₀ of 0.26 µM. nAChR agonist CMPI hydrochloride has potential for the research of nicotine dependence and many neuropsychiatric conditions associated with decreased brain cholinergic activity .

HY-110131

A 85380 hydrochloride	nAChR	Neurological Disease
A 85380 hydrochloride is a novel, high affinity neuronal nicotinic acetylcholine receptor (nAChR) agonist. A 85380 hydrochloride exhibits selectivity for the α4β2 nAChR subtypes. A 85380 hydrochloride has a broad-spectrum analgesic profile .

HY-157958

*α7 nAChR* Modulator-3**	nAChR	Neurological Disease
α7 nAChR modulator-3 (Compound 6p) is a α7 nAChR positive allosteric Modulator with a IC₅₀ value of 1.3 μM. α7 nAChR Modulator-3 can be used to inhibit auditory gating defects in a mouse schizophrenic model .

HY-N12511

Aristoquinoline	nAChR	Neurological Disease
Aristoquinoline (Compound 1) is an alkaloid can be isolated from Aristotelia chilensis. Aristoquinoline has α3β4 nAChR inhibitory activity .

HY-W014928

Anabasine hydrochloride (S)-Anabasine hydrochloride; (+)-Anabasine hydrochloride	nAChR	Neurological Disease
Anabasine ((S)-Anabasine) hydrochloride is an alkaloid that found as a minor component in tobacco (Nicotiana). Anabasine is a botanical pesticide nicotine, acts as a full agonist of nicotinic acetylcholine receptors (nAChRs). Anabasine induces depolarization of TE671 cells endogenously expressing human fetal muscle-type nAChRs (EC₅₀=0.7 µM) .

HY-145297

Flupyrimin

nAChR Neurological Disease

Flupyrimin acts as an antagonist at the insect nicotinic acetylcholine receptor (nAChR) .

Flupyrimin	nAChR	Neurological Disease
Flupyrimin acts as an antagonist at the insect nicotinic acetylcholine receptor *(nAChR)* .

HY-146405

nAChR antagonist 1	nAChR	Neurological Disease Inflammation/Immunology
nAChR antagonist 1 (compound B15) is an excellent α7 nAChR antagonist with an IC₅₀ value of 3.3 μM. nAChR antagonist 1 can be used for researching schizophrenia, Alzheimer’s disease and inflammatory disorders .

HY-110087

4BP-TQS

nAChR Neurological Disease

4BP-TQS is a potent allosteric agonist of α7 nAChR. 4BP-TQS activates nAChRs via an allosteric transmembrane site .

4BP-TQS	nAChR	Neurological Disease
4BP-TQS is a potent allosteric agonist of α7 *nAChR. 4BP-TQS activates nAChRs* via an allosteric transmembrane site .

HY-10019

Varenicline CP 526555	nAChR	Neurological Disease Inflammation/Immunology Cancer
Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-10020

Varenicline Hydrochloride CP 526555 hydrochloride	nAChR	Neurological Disease Inflammation/Immunology
Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-10021

Varenicline Tartrate CP 526555-18	nAChR ERK p38 MAPK	Others Neurological Disease
Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-10019A

Varenicline dihydrochloride CP 526555 dihydrochloride	nAChR	Neurological Disease Inflammation/Immunology
Varenicline (CP 526555-18) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-138879A

(Rac)-CP-601927 hydrochloride	nAChR	Neurological Disease
(Rac)-CP-601927 hydrochloride is the racemate of CP-601927. CP-601927 is a nAChR agonist with Ki values 1.2 nM and 102 nM for α4β2 and α3β4 nAChR, respectively .

HY-10021R

Varenicline Tartrate (Standard)	nAChR ERK p38 MAPK	Others Neurological Disease
Varenicline (Tartrate) (Standard) is the analytical standard of Varenicline (Tartrate). This product is intended for research and analytical applications. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-131001

DPNB-ABT594	nAChR	Neurological Disease
DPNB-ABT594 is a nitrobenzyl-caged ABT594 (HY-14316A) and activates *nAChRs* containing the α4β2 subunits with good selectivity than the α7 subunit. DPNB-ABT594 can be used to map the distribution of nAChRs on neurons of the medial habenula (MHb) and helps to gain a deeper understanding of the nAChR‐mediated Ca ²⁺ signalling in the MHb .

HY-152170

bPiDI	nAChR	Neurological Disease
bPiDI is a novel selective α6β2 nicotinic receptor antagonist. bPiDI inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs .

HY-10019S1

Varenicline-15N,13C,d2 CP 526555-15N,13C,d2	nAChR Isotope-Labeled Compounds	Neurological Disease Inflammation/Immunology Cancer
Varenicline- ¹⁵N, ¹³C,d₂ is ¹⁵N and deuterated labeled Varenicline (HY-10019). Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀=250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-B1532

Anabasine (S)-Anabasine; (+)-Anabasine	nAChR	Neurological Disease
Anabasine ((S)-Anabasine) is an alkaloid that found as a minor component in tobacco (Nicotiana). Anabasine is a botanical pesticide nicotine, acts as a full agonist of nicotinic acetylcholine receptors (nAChRs). Anabasine induces depolarization of TE671 cells endogenously expressing human fetal muscle-type nAChRs (EC₅₀=0.7 µM) .

HY-B0823

Acetamiprid	nAChR	Neurological Disease
Acetamiprid is a neonicotinoid insecticide used worldwide. Acetamiprid is a nicotinic acetylcholine receptor (nAChR) agonist, and is shown to be associated with neuromuscular and reproductive disorders .

HY-105170B

ABT-418 hydrochloride	nAChR	Neurological Disease
ABT-418 hydrochloride is a potent and selective agonist of *nAChRs* with cognitive enhancing and anxiolytic activities. ABT-418 hydrochloride activates cholinergic channel and can be used for research of Alzheimer's disease .

HY-B1552B

Benzoquinonium dibromide	nAChR	Neurological Disease
Benzoquinonium dibromide is a nicotinic acetylcholine receptors (nAChRs) antagonist, with an IC₅₀ of 0.46 μM. Benzoquinonium dibromide can block neuromuscular and ganglionic transmission .

HY-107680

3-Pyr-Cytisine 3-Pyr-Cyt	nAChR	Neurological Disease
3-Pyr-Cytisine (3-Pyr-Cyt) is a cytisine derivative. 3-Pyr-Cytisine is a very weak α4β2 nAChR partial agonist that has been studied as an antidepressant .

HY-110121

NS3861 fumarate	nAChR	Neurological Disease
NS3861 fumarate is an agonist of nicotinic acetylcholine receptors (nAChRs) and binds with high affinity to heteromeric α3β4 nAChR. The binding K_i values of 0.62, 25, 7.8, 55 nM for α3β4, α3β2, α4β4, α4β2, respectively .

HY-110121A

NS3861	nAChR	Neurological Disease
NS3861 is an agonist of nicotinic acetylcholine receptors (nAChRs) and binds with high affinity to heteromeric α3β4 nAChR. The binding K_i values of 0.62, 25, 7.8, 55 nM for α3β4, α3β2, α4β4, α4β2, respectively .

HY-124874

(rel)-Asperparaline A (rel)-Aspergillimide; (rel)-VM55598	nAChR	Neurological Disease
(rel)-Asperparaline A ((rel)-Aspergillimide), an anthelmintic metabolite, is isolated from okara that has been fermented with Aspergillus japonicas JV-23. (rel)-Asperparaline A is also a potent and selective antagonist of *nAChR*. (rel)-Asperparaline A exhibits paralytic activity in silk worms .

HY-N2326

(±)-Anatoxin A fumarate	nAChR	Neurological Disease
(±)-Anatoxin A fumarate is a natural alkaloid isolated from freshwater cyanobacterium.(±)-Anatoxin A fumarate is a potent nicotinic receptor agonist and exhibits K_i values of 1.25 nM and 1.84 μM for binding to putative α4β2-type nAChR and α7-type nAChR in rat brain membranes, respectively. (±)-Anatoxin A fumarate stimulates [ ³H]-dopamine release from rat striatal synaptosomes (EC₅₀=134 nM) .

HY-B0118A

Vecuronium bromide ORG NC 45	nAChR	Neurological Disease Cancer
Vecuronium (ORG NC 45) bromide is a non-depolarizing neuromuscular blocking agent that also acts as a nicotinic acetylcholine receptor (nAChR) inhibitor, a muscle relaxant, and can be used for pre-surgical anesthesia .

HY-10019AS1

Varenicline-d4 hydrochloride	Isotope-Labeled Compounds	Inflammation/Immunology
Varenicline-d₄ hydrochloride is a deuterium labeled Varenicline (dihydrochloride) (HY-10019A) . Varenicline (CP 526555) dihydrochloride is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC₅₀ value of 2.3 μM. Varenicline dihydrochloride is a full agonist for α3β4 and α7 nAChRs with EC₅₀ values of 55 μM and 18 μM, respectively . Varenicline dihydrochloride is a nicotinic ligand based on the structure of cytosine, and has the potential for smoking cessation treatment .

HY-P5306

α-Conotoxin TxID	nAChR	Neurological Disease
α-Conotoxin TxID is a potent α3β4 nAChR antagonist with an IC₅₀ value of 12.5 nM. α-Conotoxin TxID has weak inhibition activity of closely related α6/α3β4 nAChR (IC₅₀= 94 nM). α-Conotoxin TxID has the potential for novel smoking cessation drug development .

HY-B0379A

Adiphenine hydrochloride	nAChR	Neurological Disease
Adiphenine hydrochloride is a non-competitive inhibitor of nicotinic acetylcholine receptor (nAChR), with an IC₅₀s of 1.9, 1.8, 3.7, and 6.3 µM for α1, α3β4, α4β2, and α4β4, respectively. Adiphenine hydrochloride has anticonvulsant effects .

HY-145295

Flupyradifurone	nAChR	Infection
Flupyradifurone is a systemic *nAChR* agonist that interferes with signal transduction in the central nervous system of sucking pests. Flupyradifurone can be used as a butenolide insecticide .

HY-A0106

Levamisole 3 Publications Verification (-)-Tetramisole	nAChR Parasite	Infection Inflammation/Immunology Cancer
Levamisole ((-)-Levamisole), an anthelmintic agent with immunomodulatory properties. Levamisole acts as a positive allosteric modulator (PAM) for the α3β2 (EC₅₀=300 μM) and α3β4 (EC₅₀=100 μM) subtype of nAChRs. Orally active .

HY-N10132

Microgrewiapine A	nAChR	Infection Neurological Disease
Microgrewiapine A is an antagonist of *nAChR. Microgrewiapine A inhibits hα4β2* and hα3β4 activity with 60% and 70% inhibition, respectively. Microgrewiapine A has selective cytotoxic against HT-29 human colon cancer cells with an IC₅₀ of 6.8 μM .

HY-135483A

AR-R17779 hydrochloride	nAChR	Neurological Disease
AR-R17779 hydrochloride is a potent and selective full agonist of *nAChR, with K_is of 92 and 16000 nM for α7 and α4β2* subtype, respectively. AR-R17779 hydrochloride can improve learning and memory in rats. AR-R17779 hydrochloride also has anxiolytic activity. AR-R17779 hydrochloride can reduce inflammation by activating antiinflammatory cholinergic (vagal) pathways .

HY-105670A

PHA-543613 hydrochloride	nAChR	Neurological Disease
PHA-543613 hydrochloride is an oral or active α7 nAChR agonist with brain permeability, For α3β4, α1β1γδ, α4β2 and 5-HT3 receptors selective. PHA-543613 hydrochloride affects sensory gating and memory in an in vivo model of schizophrenia .

HY-A0106R

Levamisole (Standard)		Infection Inflammation/Immunology Cancer
Levamisole (Standard) is the analytical standard of Levamisole. This product is intended for research and analytical applications. Levamisole ((-)-Levamisole), an anthelmintic agent with immunomodulatory properties. Levamisole acts as a positive allosteric modulator (PAM) for the α3β2 (EC₅₀=300 μM) and α3β4 (EC₅₀=100 μM) subtype of nAChRs. Orally active .

HY-P1271

Catestatin	nAChR	Cardiovascular Disease
Catestatin is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin is an endogenous peptide that regulates cardiac function and blood pressure . Catestatin is a non-competitive nicotinic antagonist acting through nicotinic acetylcholine receptors (nAChRs) to inhibit catecholamine release .

HY-59201A

A-582941 dihydrochloride	nAChR 5-HT Receptor	Neurological Disease
A-582941 dihydrochloride is a potent, selective and brain-penetrant partial agonist of α7 nAChR, with K_is of 10.8 and 16.7 nM in rat brain membranes and human frontal cortex, respectively. A-582941 dihydrochloride also binds to human 5-HT₃ receptor with a K_i of 150 nM. A-582941 has the potential for cognitive deficits associated with various neurodegenerative and psychiatric disorders research .

HY-P1271A

Catestatin TFA	nAChR	Cardiovascular Disease
Catestatin TFA is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin TFA is an endogenous peptide that regulates cardiac function and blood pressure . Catestatin TFA is a non-competitive nicotinic antagonist acting through nicotinic acetylcholine receptors (nAChRs) to inhibit catecholamine release .

HY-128575

BNC375	nAChR	Neurological Disease
BNC375 is a potent, selective, and orally available type I positive allosteric modulator of α7 nAChRs with an EC₅₀ of 1.9 μM. BNC375 exhibits good CNS-agent like properties and clinical candidate potential. .

HY-P5823

Azemiopsin	nAChR	Neurological Disease
Azemiopsin is a potent nicotinic acetylcholine receptor (nAChR) inhibitor with IC₅₀s of 0.18 μM and 22 μM against T. californica nAChR and human α7 nAChR, respectively. Azemiopsin blocks acetylcholine-induced currents in Xenopus oocytes heterologously expressing human muscle-type nAChR .

HY-107669

nAChR-IN-1 hydrochloride	nAChR	Neurological Disease
nAChR-IN-1 (hydrochloride) is a tetramethylpiperidine heptanoate, a selective nicotinic acetylcholine receptor (nAChR) inhibitor that inhibits *nAChRs lacking α5, α6, or β3 subunits. nAChR*-IN-1 has the effect of preventing nerve disorder, can be used for nicotinic acetylcholine receptor dysfunction or neurological disorders research .

HY-138953

Epiboxidine	nAChR	Neurological Disease
Epiboxidine is a potent and selective neural nAChR agonist with K_is of 0.46 nM and 1.2 nM for rat and human α4β2 nAChRs, respectively. Epiboxidine is a methylisoxazole analog of the alkaloid Epibatidine, and is also an analog of another nAChR agonist, ABT 418 .

HY-138953A

Epiboxidine hydrochloride	nAChR	Neurological Disease
Epiboxidine hydrochloride is a potent and selective neural nAChR agonist with K_is of 0.46 nM and 1.2 nM for rat and human α4β2 nAChRs, respectively. Epiboxidine hydrochloride is a methylisoxazole analog of the alkaloid Epibatidine, and is also an analog of another nAChR agonist, ABT 418 .

Cat. No.	Product Name

HY-L062

Neurotransmitter Receptor Compound Library

1,806 compounds

Neurotransmitter (NT) receptors, also known as neuroreceptors, are a broadly diverse group of membrane proteins that bind neurotransmitters for neuronal signaling. There are two major types of neurotransmitter receptors: ionotropic and metabotropic. Ionotropic receptors are ligand-gated ion channels, meaning that the receptor protein includes both a neurotransmitter binding site and an ion channel. The binding of a neurotransmitter molecule (the ligand) to the binding site induces a conformational change in the receptor structure, which opens, or gates, the ion channel. The term “metabotropic receptors” is typically used to refer to transmembrane G-protein-coupled receptors. Metabotropic receptors trigger second messenger-mediated effects within cells after neurotransmitter binding.

In some neurological diseases, the neurotransmitter receptor itself appears to be the target of the disease process. Many neuroactive drugs act by modifying neurotransmitter receptors. A better understanding of neurotransmitter receptor changes in disease may lead to improvements in therapy.

MCE designs a unique collection of 1,806 compounds targeting a variety of neurotransmitter receptors. MCE Neurotransmitter Receptor Compound Library is a useful tool for neurological diseases drug discovery.

HY-L069

Anti-Alzheimer's Disease Compound Library

1,390 compounds

Alzheimer’s Disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Despite the significant public health issue that it poses, only few medical treatments have been approved for Alzheimer’s Disease (AD) and these act to control symptoms rather than alter the course of the disease. Discovery of new therapeutic approaches depends on the study of pathology of AD. Recent research findings have led to greater understanding of disease neurobiology in Alzheimer's Disease (AD) and identification of unique targets for drug development. Several important mechanisms have been proposed to explain the underlying pathology of AD, such as Amyloid cascade hypothesis, Tau hypothesis and Cholinergic hypothesis, etc.

MCE offers a unique collection of 1,390 compounds with anti-Alzheimer’s Disease activities or targeting the unique targets of AD. MCE Anti-Alzheimer’s Disease Compound Library is a useful tool for exploring the mechanism of AD and discovering new drugs for AD.

HY-L085

Anti-Parkinson's Disease Compound Library

1,354 compounds

Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.

MCE offers a unique collection of 1,354 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

HY-L086

Neurodegenerative Disease-related Compound Library

2,255 compounds

Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.

MCE offers a unique collection of 2,255 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

Cat. No.	Product Name	Target	Research Area

HY-P1271

Catestatin	nAChR	Cardiovascular Disease
Catestatin is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin is an endogenous peptide that regulates cardiac function and blood pressure . Catestatin is a non-competitive nicotinic antagonist acting through nicotinic acetylcholine receptors (nAChRs) to inhibit catecholamine release .

HY-P3654

α-Conotoxin S IA	nAChR	Neurological Disease
α-Conotoxin SIA is a selective nicotinic acetylcholine receptor (nAChR) antagonist with high affinity for the muscle nAChR. α-Conotoxin SIA preferentially targets the α/δ interface of the muscle nAChR in mouse muscle. In contrast, for Torpedo nAChR, α-Conotoxin SIA has a much higher affinity for the α/γ than for the α/δ interface .

HY-P5188A

Waglerin-1

nAChR GABA Receptor Neurological Disease

Waglerin-1, a 22-amino acid peptide, is a competitive antagonist of the muscle nicotinic receptor (nAChR) .

HY-P0099

Pentapeptide-3	Peptides	Others
Pentapeptide-3 is a pentapeptide fragment of neurotoxin waglerin-1, it can be extracted from the venom of Temple Viper. Pentapeptide-3 is a competitive antagonist of nicotinic acetylcholine receptors (nAChRs), it can blocks nerves at the post-synaptic membrane. Pentapeptide-3 has anti-aging effects and it can be used together with other cosmetic peptides .

HY-P5306

α-Conotoxin TxID	nAChR	Neurological Disease
α-Conotoxin TxID is a potent α3β4 nAChR antagonist with an IC₅₀ value of 12.5 nM. α-Conotoxin TxID has weak inhibition activity of closely related α6/α3β4 nAChR (IC₅₀= 94 nM). α-Conotoxin TxID has the potential for novel smoking cessation drug development .

HY-P1271A

Catestatin TFA	nAChR	Cardiovascular Disease
Catestatin TFA is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin TFA is an endogenous peptide that regulates cardiac function and blood pressure . Catestatin TFA is a non-competitive nicotinic antagonist acting through nicotinic acetylcholine receptors (nAChRs) to inhibit catecholamine release .

HY-P5823

Azemiopsin	nAChR	Neurological Disease
Azemiopsin is a potent nicotinic acetylcholine receptor (nAChR) inhibitor with IC₅₀s of 0.18 μM and 22 μM against T. californica nAChR and human α7 nAChR, respectively. Azemiopsin blocks acetylcholine-induced currents in Xenopus oocytes heterologously expressing human muscle-type nAChR .

HY-P5839

α-Conotoxin MrIC	nAChR	Neurological Disease
α-Conotoxin MrIC is an *α7nAChR* biased agonist. α-Conotoxin MrIC exclusively activates *α7nAChR* regulated by type II positive allosteric modulators, including PNU120596. α-Conotoxin MrIC can be used to study neurological diseases and also to probe the pharmacological properties of *α7nAChR* .

HY-P5849

αA-Conotoxin OIVA αA-OIVA	nAChR	Neurological Disease
αA-Conotoxin OIVA (αA-OIVA) is a selective *nAChR* antagonist with an IC₅₀ of 56 nM against mammalian fetal muscle *nAChR*. αA-Conotoxin OIVA is a peptide that can be derived from conotoxin. αA-Conotoxin OIVA paralyzes muscles .

HY-P1269

α-Conotoxin AuIB	nAChR	Neurological Disease
α-Conotoxin AuIB, a potent and selective α3β4 nicotinic acetylcholine receptor (nAChR) antagonist, blocks α3β4 nAChRs expressed in Xenopus oocytes with an IC₅₀ of 0.75 μM .

HY-P5149

αC-Conotoxin PrXA αC-PrXA	nAChR	Neurological Disease
αC-Conotoxin PrXA is a paralytic peptide neurotoxin and a competitive *nAChR* antagonist, with IC₅₀s of 1.8 nM (α1β1εδ, adult) and 3.0 nM (α1β1γδ, fetal), respectively. αC-Conotoxin PrXA competes with α-bungarotoxin at the α/δ and α/γ subunit interfaces of the nAChR, shows high specificity against neuromuscular nAChR .

HY-P1268

α-Conotoxin PIA	nAChR	Neurological Disease
α-Conotoxin PIA is a nicotinic acetylcholine receptor (nAChR) antagonist that targets nAChR subtypes containing α6 and α3 subunits. α-Conotoxin PIA has the potential for the research of Parkinson’s disease, and schizophrenia 。

HY-P1269A

α-Conotoxin AuIB TFA 1 Publications Verification	nAChR	Neurological Disease
α-Conotoxin AuIB TFA, a potent and selective α3β4 nicotinic acetylcholine receptor (nAChR) antagonist, blocks α3β4 nAChRs expressed in Xenopus oocytes with an IC₅₀ of 0.75 μM .

HY-P1268A

α-Conotoxin PIA TFA	nAChR	Neurological Disease
α-Conotoxin PIA TFA is a nicotinic acetylcholine receptor (nAChR) antagonist that targets nAChR subtypes containing α6 and α3 subunits. α-Conotoxin PIA has the potential for the research of Parkinson’s disease, and schizophrenia 。

HY-P1264F

FITC-α-Bungarotoxin	nAChR	Neurological Disease
FITC-α-Bungarotoxin is the FITC labelled α-Bungarotoxin (HY-P1264). α-Bungarotoxin is a competitive antagonist at nicotinic acetylcholine receptors (nAChRs) .

HY-P1264F1

Biotin-α-Bungarotoxin	nAChR	Neurological Disease
Biotin-α-Bungarotoxin is the Biotin labelled α-Bungarotoxin (HY-P1264). α-Bungarotoxin is a competitive antagonist at nicotinic acetylcholine receptors (nAChRs) .

HY-P1267

α-Conotoxin PnIA	nAChR	Neurological Disease
α-Conotoxin PnIA, a potent and selective antagonist of the mammalian α7 nAChR, has the potential for the research of neurological conditions such as neuropathic pain and Alzheimer’s disease .

HY-P1270

α-Conotoxin Im-I	nAChR	Neurological Disease
α-Conotoxin Im-I is a selective α7/α9 nAChR antagonist, blocking α7 nicotinic receptors with the highest apparent affinity, while having an 8-fold lower affinity for homomeric α9 nicotinic receptors. α-Conotoxin Im-I is toxic and induces seizures in rodents. α-Conotoxin Im-I is a tool for studying neuronal *nAChR* .

HY-P1267A

α-Conotoxin PnIA TFA	nAChR	Neurological Disease
α-Conotoxin PnIA TFA, a potent and selective antagonist of the mammalian α7 nAChR, has the potential for the research of neurological conditions such as neuropathic pain and Alzheimer’s disease .

HY-P5148

α-Conotoxin BuIA	nAChR	Neurological Disease
α-Conotoxin BuIA is a paralytic peptide neurotoxin and a competitive *nAChR* antagonist, with IC₅₀s of 0.258 nM (α6/α3β2), 1.54 nM (α6/α3β4), 5.72 nM (α3β2), respectively. α-Conotoxin BuIA can be used to distinguish nAChRs containing β2- and β4-subunit, respectively. α-Conotoxin BuIA distinguishes among αxβ2 nAChRs with a rank order potency of α6>α3>α2>α4 .

HY-P5844

α-Conotoxin AuIA	nAChR	Neurological Disease
α-Conotoxin AuIA is a potent and selective α3β4 n-nAChR inhibitor. α-Conotoxin AuIA is a α-conotoxin that can be isolated from Conus aulicus .

HY-P5848

αO-Conotoxin GeXIVA	nAChR	Neurological Disease
αO-Conotoxin GeXIVA is a potent α9α10 nAChR antagonist with an IC₅₀ of 12 nM against rat α9α10. αO-Conotoxin GeXIVA shows analgesic in animal models of pain .

HY-P5147

α-Conotoxin GID	nAChR	Neurological Disease
α-Conotoxin GID is a paralytic peptide neurotoxin and a selective antagonist of *nAChR, with IC₅₀s of 5 nM (α7), 3 nM (α3β2)， 150 nM (α4β2), respectively. α-Conotoxin GID is small disulfide-rich peptide, with potential to inhibit chronic pain. α-Conotoxin GID contains a C-terminal carboxylate, thus substitution with a C-terminal carboxamide results in loss of α4β2 nAChR*. α-Conotoxin GID can be isolated from the Conus species .

HY-125777A

α-Conotoxin Vc1.1 TFA	nAChR	Neurological Disease
α-Conotoxin Vc1.1 TFA is a disulfide-bonded peptide isolated from Conus victoriae and is a selective *nAChR* antagonist. α-Conotoxin Vc1.1 TFA inhibits α3α5β2, α3β2 and α3β4 with IC₅₀s of 7.2 μM, 7.3 μM and 4.2 μM, respectively, and has less inhibitory effect on other nAChR subtypes. α-Conotoxin Vc1.1 TFA has the potential for neuropathic pain reserach .

HY-P1050A

COG 133 TFA 1 Publications Verification	nAChR	Neurological Disease Inflammation/Immunology
COG 133 TFA is a fragment of Apolipoprotein E (APOE) peptide. COG 133 TFA competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 TFA is also a *nAChR* antagonist with an IC₅₀ of 445 nM .

HY-137788

α-Conotoxin GI	nAChR	Neurological Disease
α-Conotoxin GI has high affinity for *nAChR*.α-Conotoxin GI is a short peptide toxin that can be isolated from the venom of Conus geographus.α-Conotoxin GI has the similar activity with neuromuscular blocking agent .

HY-P5841

α-Conotoxin LtIA	nAChR	Neurological Disease
α-Conotoxin LtIA is an α3β2 nAChR blocker (IC₅₀=9.8 nM), that can be obtained from Conus litteratus venom. Alpha-Conotoxin LtIA can be used in the study of neurological diseases (such as Parkinson's disease, pain) .

HY-P5845

α-Conotoxin RgIA α-RgIA	nAChR	Neurological Disease
α-Conotoxin RgIA (α-RgIA) is a specific α9α10 nAChR antagonist. α-Conotoxin RgIA can be obtained from Conus regius venom. α-Conotoxin RgIA can be used in the study of neurological diseases .

HY-P3653

α-Conotoxin M I	mAChR nAChR	Neurological Disease
α-Conotoxin M I is a potent and selective inhibitor of mAChR and α1β1γδ nAChR, but has no effect on nicotine-stimulated dopamine release. α-Conotoxins are small, disulfide-rich peptides that competitively inhibit muscle and neuronal nicotinic AChRs .

HY-P1266

α-Conotoxin EI	nAChR	Neurological Disease
α-Conotoxin EI is a selective nicotinic acetylcholine α1β1γδ receptor (nAChR) antagonist (IC₅₀=187 nM) and an α3β4 receptor inhibitor. α-Conotoxin EI can block muscle and ganglionic receptors .

HY-P1264

α-Bungarotoxin	nAChR	Neurological Disease
α-Bungarotoxin is a competitive antagonist at nicotinic acetylcholine receptors (nAChRs). α-Bungarotoxin, a selective α7 receptor blocker, blocks α7 currents with an IC₅₀ of 1.6 nM and has no effects on α3β4 currents at concentrations up to 3 μM .

HY-P5852

α-Conotoxin EIIB Alpha-conotoxin EIIB	nAChR	Neurological Disease
α-Conotoxin EIIB (Alpha-conotoxin EIIB) is a toxin peptide that can be obtained from Conus ermineus. α-Conotoxin EIIB binds to *nAChR* (K_i=2.2 nM). α-Conotoxin EIIB can be used in the study of neurological diseases such as schizophrenia, drug addiction, Alzheimer's disease, and Parkinson's disease .

HY-P5146

α-Conotoxin PeIA	nAChR Calcium Channel GABA Receptor	Neurological Disease
α-Conotoxin PeIA is an analgesic α-conotoxin.α-Conotoxin PeIA inhibits the α6β4, α9α10 and α3β2 *nAChR*.α-Conotoxin PeIA is also a potent inhibitor of N-type calcium channel via GABAB receptor activation .

HY-P1365

α-Conotoxin MII α-CTxMII	nAChR	Neurological Disease
α-Conotoxin MII (α-CTxMII), a 16-amino acid peptide from the venom of the marine snail Conus magus, potently blocks nicotinic acetylcholine receptors (nAChRs) composed of α3β2 subunits, with an IC₅₀ of 0.5 nM. α-Conotoxin MII (α-CTxMII) potently blocks β3-containing neuronal nicotinic receptors .

HY-P1365A

α-Conotoxin MII TFA α-CTxMII TFA	nAChR	Neurological Disease
α-Conotoxin MII TFA (α-CTxMII TFA), a 16-amino acid peptide from the venom of the marine snail Conus magus, potently blocks nicotinic acetylcholine receptors (nAChRs) composed of α3β2 subunits, with an IC₅₀ of 0.5 nM. α-Conotoxin MII TFA (α-CTxMII TFA) potently blocks β3-containing neuronal nicotinic receptors .

HY-P5850

α-Conotoxin Bt1.8	nAChR	Neurological Disease
α-Conotoxin Bt1.8 is a potent α6/α3β2β3 and α3β2 nAChRs inhibitor with IC₅₀s of 2.1 nM and 9.4 nM against rat α6/α3β2β3 and α3β2, respectively .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1532

Anabasine (S)-Anabasine; (+)-Anabasine	Alkaloids Piperidine Alkaloids Structural Classification Nicotiana tabacum L. Source classification Pyridine Alkaloids Solanaceae Plants	nAChR
Anabasine ((S)-Anabasine) is an alkaloid that found as a minor component in tobacco (Nicotiana). Anabasine is a botanical pesticide nicotine, acts as a full agonist of nicotinic acetylcholine receptors (nAChRs). Anabasine induces depolarization of TE671 cells endogenously expressing human fetal muscle-type nAChRs (EC₅₀=0.7 µM) .

HY-N12511

Aristoquinoline	Structural Classification Alkaloids Elaeocarpaceae Source classification Aristotelia chilensis (Molina) Stuntz Quinoline Alkaloids Plants	nAChR
Aristoquinoline (Compound 1) is an alkaloid can be isolated from Aristotelia chilensis. Aristoquinoline has α3β4 nAChR inhibitory activity .

HY-124874

(rel)-Asperparaline A (rel)-Aspergillimide; (rel)-VM55598	Alkaloids Microorganisms Pyrrole Alkaloids Source classification	nAChR
(rel)-Asperparaline A ((rel)-Aspergillimide), an anthelmintic metabolite, is isolated from okara that has been fermented with Aspergillus japonicas JV-23. (rel)-Asperparaline A is also a potent and selective antagonist of *nAChR*. (rel)-Asperparaline A exhibits paralytic activity in silk worms .

HY-N10132

Microgrewiapine A	Malvaceae Structural Classification Alkaloids Microcos paniculata L. Other Alkaloids Source classification Plants	nAChR
Microgrewiapine A is an antagonist of *nAChR. Microgrewiapine A inhibits hα4β2* and hα3β4 activity with 60% and 70% inhibition, respectively. Microgrewiapine A has selective cytotoxic against HT-29 human colon cancer cells with an IC₅₀ of 6.8 μM .

HY-114791

Lobelanidine	Structural Classification Alkaloids Lobelia tupa L. Other Alkaloids Source classification Campanulaceae Plants	nAChR
Lobelanidine is an antagonist for nicotinic acetylcholine receptor (nAChR), which inhibits α7 nAChR response and α3β2/α3β4 nAChR responses, with IC₅₀ of 2.8 and 8.2 μM .

HY-121027

Anagyrine (-)-Anagyrine; Monolupine; Rhombinine	Alkaloids Piperidine Alkaloids Structural Classification Classification of Application Fields Leguminosae Source classification Plants Disease Research Fields Lupinus albus Linn. Cancer	mAChR nAChR
Anagyrine ((-)-Anagyrine) is a quinolizidine alkaloid that has been found in Lupinus albus. Anagyrine binds to muscarinic and nicotinic acetylcholine receptors with IC₅₀ values of 132 and 2096 µM respectively. Anagyrine is a potent and effective desensitizer of *nAChR, and Anagyrine can directly, without metabolism, desensitize nAChR* .

HY-121027A

Anagyrine hydrochloride (-)-Anagyrine hydrochloride; Monolupine hydrochloride; Rhombinine hydrochloride	Structural Classification Alkaloids Piperidine Alkaloids Leguminosae Source classification Plants Sophora flavescens Aiton	mAChR nAChR
Anagyrine ((-)-Anagyrine) hydrochloride is a quinolizidine alkaloid that has been found in Lupinus albus. Anagyrine hydrochloride binds to muscarinic and nicotinic acetylcholine receptors with IC₅₀ values of 132 and 2096 µM respectively. Anagyrine hydrochloride is a potent and effective desensitizer of *nAChR, and Anagyrine hydrochloride can directly, without metabolism, desensitize nAChR* .

HY-107670

Dihydro-β-erythroidine hydrobromide 1 Publications Verification DHβE hydrobromide	Alkaloids Piperidine Alkaloids Leguminosae Source classification Plants Erythrina	nAChR
Dihydro-β-erythroidine (DHβE) hydrobromide is a potent, orally active, and competitive antagonist of neuronal *nAChRs. Dihydro-β-erythroidine hydrobromide shows selectivity for α4β4 and α4β2 nAChRs, with IC₅₀*s of 0.19 and 0.37 μM, respectively. Antidepressant-like activities .

HY-N3610

Coclaurine	Alkaloids Structural Classification Source classification Phenols Polyphenols Plants Lauraceae Isoquinoline Alkaloids Lindera aggregata (Sims) Kosterm.	nAChR
Coclaurine is a class of tetrahydroisoquinoline alkaloids that can be isolated from Sarcopetalum harveyanum. Coclaurine is a nicotinic acetylcholine receptor (nAChRs) antagonist .

HY-W795027

Anatoxin-a ATX-a	Structural Classification Alkaloids Microorganisms Pyrrole Alkaloids Source classification	nAChR Cholinesterase (ChE)
Anatoxin-a (ATX-a) is a neurotoxic alkaloid. Anatoxin-a acts as both a nicotinic acetylcholine receptor (nAChR) agonist and an Acetylcholinesterase (AChE) inhibitor .

HY-W705106

(-)-Coclaurine hydrochloride (-)-(S)-Coclaurine hydrochloride; (S)-Coclaurine hydrochloride; l-Coclaurine hydrochloride	Structural Classification Alkaloids Piperidine Alkaloids Source classification Cocculus laurifolius DC. Plants Menispermaceae	nAChR
(-)-Coclaurine hydrochloride (compound I) is a class of tetrahydroisoquinoline alkaloids that can be isolated from Sarcopetalum harveyanum. (-)-Coclaurine hydrochloride is a nicotinic acetylcholine receptor (nAChRs) antagonist .

HY-13780

Vinblastine sulfate 10+ Cited Publications Vincaleukoblastine sulfate salt	Apocynaceae Alkaloids Classification of Application Fields Source classification Plants Disease Research Fields Alkaloid Dimers Cancer Catharanthus roseus (L.) G. Don	Microtubule/Tubulin Autophagy
Vinblastine sulfate is a cytotoxic alkaloid used against various cancer types. Vinblastine sulfate inhibits the formation of microtubule and suppresses nAChR with an IC₅₀ of 8.9 μM.

HY-W001909

Myosmine	Alkaloids Pyrrole Alkaloids Classification of Application Fields Nicotiana tabacum L. Source classification Pyridine Alkaloids Metabolic Disease Plants Solanaceae Disease Research Fields	nAChR
Myosmine, a specific tobacco alkaloid in nuts and nut products, has low affinity for a4b2 nicotinic acetylcholinergic receptors (nAChR) with a K_i of 3300 nM .

HY-W099757

(±)-Coniine hydrochloride 2-Propylpiperidine hydrochloride	Structural Classification Alkaloids Source classification Pyridine Alkaloids Plants Umbelliferae Conium maculatum L.	nAChR
(±)-Coniine hydrochloride (2-Propylpiperidine hydrochloride) is a potent *nAChR* agonist with an EC₅₀ value of 0.3 mM. (±)-Coniine hydrochloride shows acute toxicity with an LD₅₀ value of 7.7 mg/kg .

HY-N3359

Lupanine D-Lupanine	Alkaloids Structural Classification Microorganisms Leguminosae Source classification Plants Lupinus albus Linn.	nAChR
Lupanine (D-Lupanine) is a natural ketonic derivative of Sparteine ((+)-Sparteine (HY-W008350)) with a ganglioplegic activity. Lupanine shows binding affinity for nicotinic receptor (nAChR) with a K_i value of 500 nM .

HY-N3359B

Lupanine hydrochloride D-Lupanine hydrochloride	Structural Classification Alkaloids Leguminosae Source classification Plants Lupinus albus Linn.	nAChR
Lupanine (D-Lupanine) hydrochloride is a natural ketonic derivative of Sparteine ((+)-Sparteine (HY-W008350)) with a ganglioplegic activity. Lupanine hydrochloride shows binding affinity for nicotinic receptor (nAChR) with a K_i value of 500 nM .

HY-B0282

Acetylcholine chloride 5+ Cited Publications ACh chloride	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	nAChR Calcium Channel Endogenous Metabolite
Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs) . Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro .

HY-13780R

Vinblastine sulfate (Standard)	Apocynaceae Alkaloids Structural Classification Source classification Plants Alkaloid Dimers Catharanthus roseus (L.) G. Don	Microtubule/Tubulin Autophagy
Vinblastine (sulfate) (Standard) is the analytical standard of Vinblastine (sulfate). This product is intended for research and analytical applications. Vinblastine sulfate is a cytotoxic alkaloid used against various cancer types. Vinblastine sulfate inhibits the formation of microtubule and suppresses nAChR with an IC₅₀ of 8.9 μM.

HY-N0175

Cytisinicline 1 Publications Verification Cytisine; Sophorine; Baptitoxine	Alkaloids Classification of Application Fields Leguminosae Source classification Pyridine Alkaloids Metabolic Disease Plants Thermopsis lanceolala R.Br. Disease Research Fields	nAChR
Cytisinicline (Cytisine) is an alkaloid. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs , and partial to full agonist at β4 containing receptors and α7 receptors . Has been used medically to help with smoking cessation .

HY-N0443

N-Methylcytisine 1 Publications Verification Caulophylline	Alkaloids Piperidine Alkaloids Classification of Application Fields Leguminosae Source classification Pyridine Alkaloids Plants Sophora flavescens Aiton Disease Research Fields Inflammation/Immunology	nAChR
N-Methylcytisine (Caulophylline), a tricyclic quinolizidine alkaloid, exerts hypoglycaemic, analgesic and anti-inflammatory activities. N-methylcytisine is a selective ligand of nicotinic receptors of acetylcholine in the central nervous system and has a high affinity (K_d = 50 nM) to nicotinic acetylcholine receptors (nAChR) from squid optical ganglia .

HY-138800

Spinosad 1 Publications Verification	Structural Classification Natural Products Microorganisms Neurological Disease Classification of Application Fields Source classification Disease Research Fields Biological Pesticide Research Agricultural Research	nAChR
Spinosad, a mixture of spinosyns A and D known as fermentation products of a soil actinomycete (Saccharopolyspora spinosa), is a biological neurotoxic insecticide with a broader action spectrum. Spinosad targets the nicotinic acetylcholine receptor *(nAChRs)* of the insect nervous system. Spinosad has an excellent environmental and mammalian toxicological profile. Larvicidal activity .

HY-A0009

Galanthamine hydrobromide 10+ Cited Publications Galantamine hydrobromide	Structural Classification Alkaloids Other Alkaloids Source classification Plants Amaryllidaceae	Cholinesterase (ChE) nAChR
Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC₅₀ of 0.35 µM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α₃β₄, α₄β₂, α₆β₄ nicotinic receptors ( *nAChRs*). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) .

HY-A0009R

Galanthamine hydrobromide (Standard) Galantamine hydrobromide (Standard)	Structural Classification Alkaloids Source classification Plants Amaryllidaceae	nAChR Cholinesterase (ChE)
Galanthamine (hydrobromide) (Standard) is the analytical standard of Galanthamine (hydrobromide). This product is intended for research and analytical applications. Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC₅₀ of 0.35 μM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α₃β₄, α₄β₂, α₆β₄ nicotinic receptors ( *nAChRs*). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) .

HY-15310

Ivermectin Maximum Cited Publications 18 Publications Verification MK-933	Structural Classification Microorganisms Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Antiviral Anti-parasitic Disease Research Disease Research Fields Cancer	Flavivirus Dengue virus Parasite HIV Mitophagy HSV SARS-CoV Antibiotic Autophagy Bacterial
Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X₄ and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import . Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19 .

HY-15310R

Ivermectin (Standard)	Structural Classification Microorganisms Macrolide Antibiotics Antibiotics Source classification Antiviral Anti-parasitic Disease Research	Dengue virus Flavivirus Parasite HIV Mitophagy HSV SARS-CoV Antibiotic Autophagy Bacterial
Ivermectin (Standard) is the analytical standard of Ivermectin. This product is intended for research and analytical applications. Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X₄ and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import . Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19 .

Cat. No.	Product Name	Chemical Structure

HY-10019AS1

Varenicline-d4 hydrochloride

Varenicline-d₄ hydrochloride is a deuterium labeled Varenicline (dihydrochloride) (HY-10019A) . Varenicline (CP 526555) dihydrochloride is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC₅₀ value of 2.3 μM. Varenicline dihydrochloride is a full agonist for α3β4 and α7 nAChRs with EC₅₀ values of 55 μM and 18 μM, respectively . Varenicline dihydrochloride is a nicotinic ligand based on the structure of cytosine, and has the potential for smoking cessation treatment .

HY-10019S1

Varenicline-15N,13C,d2

Varenicline- ¹⁵N, ¹³C,d₂ is ¹⁵N and deuterated labeled Varenicline (HY-10019). Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀=250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-B0282S

Acetylcholine-d4 chloride

Acetylcholine-d₄ (chloride) is the deuterium labeled Acetylcholine chloride. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs)[1][2]. Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro[5].

HY-B0282S1

Acetylcholine-d9 chloride

Acetylcholine-d₉ (chloride) is the deuterium labeled Acetylcholine chloride. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs)[1][2]. Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro[5].

HY-B0823S

Acetamiprid-d3

Acetamiprid-d₃ is the deuterium labeled Acetamiprid. Acetamiprid is a neonicotinoid insecticide. Acetamiprid is a nAChR agonist[1].

HY-14774S

(Rac)-Monepantel-d5
(Rac)-Monepantel-d₅ is deuterium labeled Monepantel. Monepantel is organic anthelmintic, and acts as a positive allosteric modulator of a nematode-specific clade of nicotinic acetylcholine receptor (nAChR) subunits.

HY-10019S

Varenicline-d4

Varenicline-d₄ is deuterium labeled Varenicline. Varenicline (CP 526555) is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC50 value of 2.3 μM. Varenicline is a full agonist for α3β4 and α7 nAChRs with EC50 values of 55 μM and 18 μM, respectively[1]. Varenicline is a nicotinic ligand based on the structure of cytisine, has the potential for smoking cessation treatment[2].

HY-14774S1

(Rac)-Monepantel sulfone-d5
(Rac)-Monepantel sulfone-d₅ is deuterium labeled Monepantel. Monepantel is organic anthelmintic, and acts as a positive allosteric modulator of a nematode-specific clade of nicotinic acetylcholine receptor (nAChR) subunits.

HY-W001909S

Myosmine-d4
Myosmine-d₄ is the deuterium labeled Myosmine. Myosmine, a specific tobacco alkaloid in nuts and nut products, has low affinity for a4b2 nicotinic acetylcholinergic receptors (nAChR) with a Ki of 3300 nM[1][2].

HY-B1395S1

Mecamylamine hydrochloride-13C4,15N

Mecamylamine (hydrochloride)- ¹³C₄, ¹⁵N is the ¹³C-labeled and ¹⁵N-labeled Mecamylamine hydrochloride. Mecamylamine hydrochloride is an orally active, nonselective, noncompetitive nAChR antagonist that can treat various neuropsychiatric disorders. Mecamylamine hydrochloride is originally used as a ganglionic blocker in treating hypertension. Mecamylamine hydrochloride can easily crosses the blood-brain barrier[1][2].

HY-106901AS

Asoxime-d4 dichloride
Asoxime-d₄ (dichloride) is the deuterium labeled Asoxime dichloride. Asoxime dichloride (HI-6) is an antagonist to acetylcholine receptors (AChRs) including the nicotinic receptor, α7 nAChR. Asoxime dichloride involves in modulating immunity response. Asoxime dichloride (HI-6) can be used as an antigen and improves vaccination efficacy in the nervous system[1].

HY-A0009S

Galanthamine-d3 hydrobromide

Galanthamine-d₃ (hydrobromide) is deuterium labeled Galanthamine (hydrobromide). Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC50 of 0.35 µM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD)[1][2][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks